Category Archives : News

Home  >>  News

Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016

On April 21, 2016, Posted by , In News, With No Comments

Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data from a combination study of Affimed’s lead candidate AFM13 and checkpoint modulators at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New…

Affimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the AACR Annual Meeting 2016

On April 21, 2016, Posted by , In News, With No Comments

Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced that the Company presented data on its EGFR-targeting TandAb immune cell engagers on Sunday, April 17, in two poster presentation at the American Association for Cancer Research (AACR) 2016 Annual Meeting…

DKFZ: Founding of an International Cancer Genome Consortium for medicine: Scientists combine data from cancer genome with information on disease progression

On April 20, 2016, Posted by , In News, With No Comments

During the American Association for Cancer Research annual meeting, members of the International Cancer Genome Consortium (ICGC) announced their entering of a new phase: The ICGCmed now combine data from cancer genome with information on disease progression. The objective of this initiative is to make optimal use of the consolidated…

Roche reports solid sales growth in the first quarter of 2016

On April 19, 2016, Posted by , In News, With No Comments

Roche CEO Severin Schwan said: “We have started the year with solid growth in both our Pharmaceuticals and Diagnostics Divisions. The marketing applications of important investigational medicines are well underway. The FDA granted priority review for atezolizumab in two indications and breakthrough therapy designation for ocrelizumab in primary progressive multiple…

DKFZ: Endogenous oxidants: New methods for monitoring processes in the organism

On April 19, 2016, Posted by , In News, With No Comments

Diet, physical activity, infection, cancer, and possibly aging are all factors that can have an impact on the oxidation state of cells and tissues. Scientists from the German Cancer Research Center (DKFZ) have now developed two novel biological measuring systems that facilitate better analysis of disease-relevant changes in the oxidation…

Uni Heidelberg: Predicting Cell Behaviour with a Mathematical Model

On April 18, 2016, Posted by , In News, With No Comments

Heidelberg physicists develop new software for the life sciences Scientists from Heidelberg University have developed a novel mathematical model to explore cellular processes: with the corresponding software, they now are able to simulate how large collections of cells behave on given geometrical structures. The software supports the evaluation of microscope-based…

Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab

On April 18, 2016, Posted by , In News, With No Comments

Leica Biosystems and Merrimack Pharmaceuticals (NASDAQ: MACK) today announced a strategic partnership to develop companion diagnostic assays to aid in identification of patients who might best respond to current and future oncology therapies developed by Merrimack. The assays will be designed using Advanced Cell Diagnostics’ (ACD’s) RNAscope technology and will…

Merck Appoints Maya Martinez-Davis as Global Head of Oncology

On April 14, 2016, Posted by , In News, With No Comments

Darmstadt, Germany, April 14, 2016 – Merck, a leading science and technology company, today announces the appointment of Maya Martinez-Davis (46), as Global Head of Oncology Franchise for its biopharma business. She will report to Rehan Verjee, Chief Marketing and Strategy Officer of Merck’s Healthcare business sector, and will be…

EMBL: Revealing structure of nuclear pore’s inner ring

On April 14, 2016, Posted by , In News, With No Comments

Study published today in Science sheds light on structure of nuclear pore complex, which plays a crucial role in controlling molecular traffic to a cell’s nucleus It was a 3D puzzle with over 1000 pieces, with only a rather fuzzy outline as a guide. But scientists at EMBL have now…

Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia

On April 12, 2016, Posted by , In News, With No Comments

Venclexta is designed to help restore a cell’s ability to self-destruct and is the first medicine of its kind to be approved Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta™ (venetoclax) for the treatment of people with…